AustralianSuper Pty Ltd Sells 189,845 Shares of United Therapeutics Corporation $UTHR

AustralianSuper Pty Ltd lowered its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 66.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 98,000 shares of the biotechnology company’s stock after selling 189,845 shares during the quarter. AustralianSuper Pty Ltd’s holdings in United Therapeutics were worth $41,083,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in UTHR. Wilmington Savings Fund Society FSB lifted its position in United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after buying an additional 49 shares in the last quarter. Chung Wu Investment Group LLC bought a new position in shares of United Therapeutics in the second quarter worth about $29,000. WealthCollab LLC lifted its position in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. grew its stake in shares of United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares during the last quarter. Finally, True Wealth Design LLC increased its holdings in shares of United Therapeutics by 738.5% in the third quarter. True Wealth Design LLC now owns 109 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 96 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on UTHR shares. Wells Fargo & Company upped their price target on United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research note on Thursday, October 30th. UBS Group upped their target price on shares of United Therapeutics from $600.00 to $645.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. Royal Bank Of Canada increased their price objective on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a report on Thursday, October 30th. Finally, HC Wainwright raised their price objective on shares of United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $509.50.

United Therapeutics Price Performance

NASDAQ UTHR opened at $467.30 on Thursday. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $519.99. The firm has a market cap of $20.12 billion, a P/E ratio of 17.71, a P/E/G ratio of 2.56 and a beta of 0.84. The stock’s 50-day moving average is $487.51 and its 200-day moving average is $418.60.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.89 by $0.27. The business had revenue of $799.50 million during the quarter, compared to analyst estimates of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.United Therapeutics’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $6.39 EPS. Equities analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current year.

Insider Buying and Selling at United Therapeutics

In other news, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $429.25, for a total transaction of $9,658,125.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 566,864 shares of company stock valued at $269,514,607 in the last ninety days. 10.30% of the stock is owned by corporate insiders.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.